PureTech Health plc (NASDAQ:PRTC – Free Report) – Research analysts at Leerink Partnrs cut their FY2024 EPS estimates for PureTech Health in a note issued to investors on Tuesday, November 19th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings per share of ($4.31) for the year, down from their previous forecast of ($4.27). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for PureTech Health’s current full-year earnings is ($4.32) per share.
Separately, Leerink Partners initiated coverage on PureTech Health in a research note on Monday, September 9th. They issued an “outperform” rating and a $45.00 target price on the stock.
PureTech Health Stock Up 2.6 %
NASDAQ:PRTC opened at $22.35 on Thursday. The firm’s fifty day moving average is $20.59 and its two-hundred day moving average is $23.33. PureTech Health has a one year low of $17.08 and a one year high of $34.00.
Hedge Funds Weigh In On PureTech Health
A hedge fund recently bought a new stake in PureTech Health stock. Birch Hill Investment Advisors LLC acquired a new stake in PureTech Health plc (NASDAQ:PRTC – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 302,000 shares of the company’s stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned approximately 1.26% of PureTech Health as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 0.04% of the company’s stock.
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Further Reading
- Five stocks we like better than PureTech Health
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Tesla Investors Continue to Profit From the Trump Trade
- Ride Out The Recession With These Dividend Kings
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- How to Calculate Inflation Rate
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
